Olli Kallioniemi

Olli Kallioniemi

Auto-generated profile, based on publicly available information

Olli Kallioniemi

Institute for Molecular Medicine Finland-FIMM, Helsinki Institute for Life Sciences-HiLIFE, University of Helsinki, Finland

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1998 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JKJuha Kononen
Juha Kononen
LBLukas Bubendorf
Lukas Bubendorf
AKAnne Kallionimeni
Anne Kallionimeni
MBMaarit Bärlund
Maarit Bärlund
PSPeter Schraml
Peter Schraml
OKOlli-P. Kallionimeni
Olli-P. Kallionimeni

1 May 2003 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
AAA. Antoniou
A. Antoniou
PPPaul Pharoah
Paul Pharoah
SNS. Narod
S. Narod
HRH.A. Risch
H.A. Risch
JEJ.E. Eyfjord
J.E. Eyfjord
DED.F. Easton
D.F. Easton

30 October 1992 in Science
Verified
Journal Article
Closed access
PDF file
AKAnne Kallioniemi
Anne Kallioniemi
OKOlli-P. Kallioniemi
Olli-P. Kallioniemi
DSDamir Sudar
Damir Sudar
DRDenis Rutovitz
Denis Rutovitz
JGJoe W. Gray
Joe W. Gray
DPDan Pinkel
Dan Pinkel
Comparative genomic hybridization produces a map of DNA sequence copy number as a function of chromosomal location throughout the entire genome. Differentially labeled test DNA and normal reference DNA are hybridized simultaneously to normal chromosome spreads. The hybridization is detected with two different fluorochromes. Regions of gain or loss of DNA sequences, such as deletions, duplications, or amplifications, are seen as changes in the ratio of the intensities of the two fluorochromes along the target chromosomes. Analysis of tumor cell lines and primary bladder tumors identified 16 different regions of amplification, many in loci not previously known to be amplified.

25 November 2002 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
PPPamela M. Pollock
Pamela M. Pollock
UHUrsula L. Harper
Ursula L. Harper
KHKatherine S. Hansen
Katherine S. Hansen
LYLaura M. Yudt
Laura M. Yudt
MSMitchell Stark
Mitchell Stark
PMPaul S. Meltzer
Paul S. Meltzer

22 February 2001 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
IHIngrid A Hedenfalk
Ingrid A Hedenfalk
DDDavid Duggan
David Duggan
YCYidong Chen
Yidong Chen
MRMichael Radmacher
Michael Radmacher
MBMichael Bittner
Michael Bittner
JTJeffrey Trent
Jeffrey Trent
Many cases of hereditary breast cancer are due to mutations in either the BRCA1 or the BRCA2 gene. The histopathological changes in these cancers are often characteristic of the mutant gene. We hypothesized that the genes expressed by these two types of tumors are also distinctive, perhaps allowing us to identify cases of hereditary breast cancer on the basis of gene-expression profiles. RNA from samples of primary tumors from seven carriers of the BRCA1 mutation, seven carriers of the BRCA2 mutation, and seven patients with sporadic cases of breast cancer was compared with a microarray of 6512 complementary DNA clones of 5361 genes. Statistical analyses were used to identify a set of genes that could distinguish the BRCA1 genotype from the BRCA2 genotype. Permutation analysis of multivariate classification functions established that the gene-expression profiles of tumors with BRCA1 mutations, tumors with BRCA2 mutations, and sporadic tumors differed significantly from each other. An analysis of variance between the levels of gene expression and the genotype of the samples identified 176 genes that were differentially expressed in tumors with BRCA1 mutations and tumors with BRCA2 mutations. Given the known properties of some of the genes in this panel, our findings indicate that there are functional differences between breast tumors with BRCA1 mutations and those with BRCA2 mutations. Significantly different groups of genes are expressed by breast cancers with BRCA1 mutations and breast cancers with BRCA2 mutations. Our results suggest that a heritable mutation influences the gene-expression profile of the cancer.

15 August 1997 in Science
Verified
Journal Article
Open access
PDF file
SASarah L. Anzick
Sarah L. Anzick
JKJuha Kononen
Juha Kononen
RWRobert L. Walker
Robert L. Walker
DADavid O. Azorsa
David O. Azorsa
MTMinna M. Tanner
Minna M. Tanner
PMPaul S. Meltzer
Paul S. Meltzer
Members of the recently recognized SRC-1 family of transcriptional coactivators interact with steroid hormone receptors to enhance ligand-dependent transcription. AIB1, a member of the SRC-1 family, was cloned during a search on the long arm of chromosome 20 for genes whose expression and copy number were elevated in human breast cancers. AIB1 amplification and overexpression were observed in four of five estrogen receptor–positive breast and ovarian cancer cell lines. Subsequent evaluation of 105 unselected specimens of primary breast cancer found AIB1 amplification in approximately 10 percent and high expression in 64 percent of the primary tumors analyzed. AIB1 protein interacted with estrogen receptors in a ligand-dependent fashion, and transfection of AIB1 resulted in enhancement of estrogen-dependent transcription. These observations identify AIB1 as a nuclear receptor coactivator whose altered expression may contribute to development of steroid-dependent cancers.